Characteristics and outcomes of feasibility study patients who received tumor board-guided therapy
| Age, y . | Sex . | Diagnosis . | Cytogenetic abnormalities and mutations . | IPSS-R score . | Tumor board recommendations and next line of therapy (bold) . | Response to next line of therapy . |
|---|---|---|---|---|---|---|
| 77 | F | MDS/MPN | +1q, +1p, ASXL1, STAG2, SF3B1, KRAS, NRAS, CEBPA | 5.5 | 1. Azacitidine-venetoclax | CR |
| 2. Bortezomib-dexamethasone | ||||||
| 3. Sorafenib-dexamethasone | ||||||
| 67 | M | MDS-EB2 | TET2 | 4.0 | 1. Cytarabine-venetoclax | CR |
| 2. Sorafenib-venetoclax | ||||||
| 3. Azacitidine-sorafenib | ||||||
| 79 | M | MDS-MLD | t(6;21), +15, -Y, PBRM1 | 4.0 | 1. Azacitidine-venetoclax | CR |
| 2. Cytarabine-venetoclax | ||||||
| 3. Mivebresib | ||||||
| 62 | M | MDS-EB1 | −20q, U2AF1, TET2 | 5.0 | 1. Decitabine | PR |
| 2. Panobinostat | ||||||
| 3. Belinostat | ||||||
| 78 | M | MDS-EB1 | −7q, DNMT3A, DDX41 | 6.5 | 1. Danazol-tretinoin | SD |
| 2. Fostamatinib | ||||||
| 3. Azacitidine-venetoclax | ||||||
| 59 | M | MDS-EB1 | CBL | 4.0 | 1. Azacitidine | SD |
| 2. Azacitidine-venetoclax | ||||||
| 3. Everolimus | ||||||
| 75 | M | MDS-MLD | inv(3p) | 2.5 | 1. Calcitriol-eltrombopag | HI |
| 2. Calcitriol-panobinostat | ||||||
| 3. Olaparib | ||||||
| 80 | M | MDS-EB1 | inv(9p), −20q, BCOR, U2AF1, DNMT3A, RUNX1, WT1 | 4.5 | 1. Azacitidine | PR |
| 2. Azacitidine-venetoclax | ||||||
| 3. Lenalidomide |
| Age, y . | Sex . | Diagnosis . | Cytogenetic abnormalities and mutations . | IPSS-R score . | Tumor board recommendations and next line of therapy (bold) . | Response to next line of therapy . |
|---|---|---|---|---|---|---|
| 77 | F | MDS/MPN | +1q, +1p, ASXL1, STAG2, SF3B1, KRAS, NRAS, CEBPA | 5.5 | 1. Azacitidine-venetoclax | CR |
| 2. Bortezomib-dexamethasone | ||||||
| 3. Sorafenib-dexamethasone | ||||||
| 67 | M | MDS-EB2 | TET2 | 4.0 | 1. Cytarabine-venetoclax | CR |
| 2. Sorafenib-venetoclax | ||||||
| 3. Azacitidine-sorafenib | ||||||
| 79 | M | MDS-MLD | t(6;21), +15, -Y, PBRM1 | 4.0 | 1. Azacitidine-venetoclax | CR |
| 2. Cytarabine-venetoclax | ||||||
| 3. Mivebresib | ||||||
| 62 | M | MDS-EB1 | −20q, U2AF1, TET2 | 5.0 | 1. Decitabine | PR |
| 2. Panobinostat | ||||||
| 3. Belinostat | ||||||
| 78 | M | MDS-EB1 | −7q, DNMT3A, DDX41 | 6.5 | 1. Danazol-tretinoin | SD |
| 2. Fostamatinib | ||||||
| 3. Azacitidine-venetoclax | ||||||
| 59 | M | MDS-EB1 | CBL | 4.0 | 1. Azacitidine | SD |
| 2. Azacitidine-venetoclax | ||||||
| 3. Everolimus | ||||||
| 75 | M | MDS-MLD | inv(3p) | 2.5 | 1. Calcitriol-eltrombopag | HI |
| 2. Calcitriol-panobinostat | ||||||
| 3. Olaparib | ||||||
| 80 | M | MDS-EB1 | inv(9p), −20q, BCOR, U2AF1, DNMT3A, RUNX1, WT1 | 4.5 | 1. Azacitidine | PR |
| 2. Azacitidine-venetoclax | ||||||
| 3. Lenalidomide |
EB, excess blasts; F, female; HI, hematologic improvement; M, male; MLD, multilineage dysplasia; PR, partial response; SD, stable disease.